These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15235393)

  • 21. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
    Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
    Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [T cells recognizing EBV-epitopes arose in co-culture of peripheral blood mononuclear cells from EB-infected patients and dendritic cells loaded with LMP2-mixed peptides].
    Xing YP; Cen XN; Tong CR; Gu JY; Cai P; Tao XY; Jin X; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):392-6. PubMed ID: 18426672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
    McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
    Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
    Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
    Bollard CM; Gottschalk S; Leen AM; Weiss H; Straathof KC; Carrum G; Khalil M; Wu MF; Huls MH; Chang CC; Gresik MV; Gee AP; Brenner MK; Rooney CM; Heslop HE
    Blood; 2007 Oct; 110(8):2838-45. PubMed ID: 17609424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
    Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
    Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
    Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
    Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
    Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
    Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
    Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.
    Hong B; Peng G; Berry L; Gottschalk S; Jung JU; Chen SY; Huang XF
    Gene Ther; 2012 Aug; 19(8):818-27. PubMed ID: 22052242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
    Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
    Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope.
    Smith C; Cooper L; Burgess M; Rist M; Webb N; Lambley E; Tellam J; Marlton P; Seymour JF; Gandhi M; Khanna R
    J Immunol; 2006 Oct; 177(7):4897-906. PubMed ID: 16982932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.